TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
TriLink BioTechnologies (TriLink ® ), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility. The 32,000-square-foot facility was specifically designed for mRNA manufacturing to support late-phase drug developers from Phase 2 to commercialization via TriLink’s robust mRNA manufacturing capabilities. The milestone opening is expected to help advance the field of mRNA-based medicine as developers flock to leverage the promising modality for a growing list of indications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418722567/en/
TriLink BioTechnologies® Cuts Ribbon on New San Diego Facility for Late Phase mRNA Drug Substance Production (Photo: TriLink BioTechnologies®)
Located in the Sorrento Valley area of San Diego, the facility features individual Grade C cleanroom suites for mRNA manufacturing, increased mRNA capacity (1g to >100g per batch), comprehensive in-house analytical services, and laboratory space for on-site quality control testing. The manufacturing suites are outfitted with state-of-the-art equipment and ready to onboard clients with late-phase manufacturing needs.
“This facility is expected to help move the needle for life-saving breakthroughs in mRNA-therapeutics,” explained Kevin Lynch, Vice President & General Manager of TriLink’s GMP Operations. “The high-quality manufacture of mRNA drug substances is critical to ensuring the safety and efficacy of this new class of medicines for patients.”
Company and site leadership and industry guests gathered on April 17 to celebrate the facility’s grand opening with a ribbon cutting, expert-led panel discussion, and site tours – all centered around a core theme: Building the Future of mRNA. The thought-provoking panel included insights on the mRNA regulatory landscape, manufacturing evolution, and next-generation tools.
TriLink has reliably delivered GMP services to drug developers since the debut of its first cGMP facility in 2015. Since then, the company’s dedicated team of scientists has provided over 1,000 clients with custom mRNA synthesis, supported 350+ programs in biopharma development pipelines, and delivered over 100 GMP mRNA manufacturing batches.
“TriLink’s depth of industry experience – which spans over 25 years – coupled with its capabilities makes for an unmatched partner,” shared Drew Burch, President of Nucleic Acid Production. “This new facility codifies our commitment to advancing the field by playing a key role in the development of mRNA-based in vivo gene editing, gene-edited cell therapies, protein replacement therapies, cancer vaccines, and infectious disease vaccines.”
In addition to CDMO services and unique mRNA, oligonucleotide, NTP, and plasmid production capabilities, TriLink has developed the award-winning CleanCap® mRNA capping technology used in the majority of approved COVID-19 mRNA and saRNA vaccines, adding momentum to the rapidly growing field.
To learn more about TriLink’s products and services, visit trilinkbiotech.com.
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.
For more information, visit trilinkbiotech.com.
About Maravai LifeSciences
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit www.maravai.com.
Forward-looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements related to the expectation that the facility will help advance the field of mRNA-based medicine and will help move the needle for life-saving breakthroughs, constitute forward-looking statements identified by words like “expect,” “estimate,” “may,” “soon,” “nears,” “slated,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, operational risks and competition. These and other risks and uncertainties are described in greater detail in the “Risk Factors” section of our most recent Annual Report on Form 10-K, as well as other reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from those contemplated by these forward-looking statements, and therefore you should not rely upon them. These forward-looking statements reflect our current views and we do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240418722567/en/
Contact information
Investor Contact: Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com
Media Contact:
Liz Robinson of CG Life
TriLink BioTechnologies
+1 312-997-2436
lrobinson@cglife.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Belkin Commits to be 100 Percent Carbon Neutral Across Its Entire Business by 20301.5.2024 02:11:00 EEST | Press release
Belkin, a leading consumer electronics brand for 40 years, published its 2023 Impact Report, announcing its plan to achieve carbon neutrality by 2030. Already on its way to becoming 100 percent carbon neutral in its global offices and operations by 2025, Belkin is driving progress beyond and into its supply chain and product life cycle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430365199/en/ Belkin Everyday Impact (Graphic: Business Wire) Belkin is taking several meaningful steps toward addressing 2030 goals, including enhancing Life Cycle Assessment (LCA) capabilities to more accurately measure its product level emissions, and enforcing accountability in its supply chain. “In a rapidly changing and interconnected world, we have a profound responsibility as a global company to lead by example and drive meaningful change in environmental sustainability, social responsibility, and ethical governance,” said Steve Malony
Dubai Launches Global Blueprint for Artificial Intelligence30.4.2024 22:16:00 EEST | Press release
Dubai has launched a blueprint for Artificial Intelligence (AI), a yearly plan that will focus on harnessing the technology’s potential to improve quality of life around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430433819/en/ Dubai launches global blueprint for artificial intelligence (Graphic: AETOSWire) The plan begins with the appointment of a CEO for AI in each government entity, and will be followed by the establishment of an AI and WEB3 Incubator, which will develop into the largest global hub for AI and technology companies. The hub will attract innovators, startups and AI leaders from around the world and support of development of their ideas into successful enterprises or real-world applications. The plan also includes the introduction of AI Week into schools and colleges to help integrate AI applications into the educational system. This will enable students to develop skills that align with futu
RTL Luxembourg Deploys Verimatrix Streamkeeper to Protect Premier Auto Racing from Piracy30.4.2024 18:45:00 EEST | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that RTL Luxembourg, the country’s leading media company, selected the Verimatrix Streamkeeper Multi-DRM solution to ensure the security of its highly valuable motorsport content and the protection of its related revenues. As one of the region’s top media outlets, RTL looks to provide high levels of trust for its content owners while also maintaining protections for its associated revenue streams. Verimatrix Streamkeeper Multi-DRM ensures the operator remains in control of its valuable digital assets and reduces costs and complexities that are all too common in other DRM schemes. “From the first contact with Verimatrix to the go-live moment, very few interactions were needed,” said Tom Weber, CTO at RTL Luxembourg. “It went seamlessly and very quick in a few days. We’re happy to see such a committed team that is striving to satisfy the cus
Laserfiche AI Document Summarization: Simplifying Content Consumption and Powering Productivity30.4.2024 17:00:00 EEST | Press release
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — today announced the availability of new generative AI-powered document summarization in Laserfiche Cloud. The release represents one landmark in the Laserfiche AI vision to transform the workplace, empowering individuals to unlock the value in their organization’s content, gain control of processes and deploy AI at scale. Organizations face the challenge of managing growing amounts of data across departments, offices and geographic locations — making it difficult to find the value hidden inside those repositories. Laserfiche AI Document Summarization achieves this by unlocking more meaningful insights into content, giving users the ability to create and share short summaries of repository entries, resulting in: Increased productivity, by reducing the time it takes to identify and consume business content Enhanced communication, by delivering concise meeting or project notes to tea
Leveraging AI, MYbank Enables Financing Services for 53 Million SMEs30.4.2024 16:41:00 EEST | Press release
MYbank, a leading digital bank in China and an associate of Ant Group, today released its 2023 Annual Report, which announces that the bank has cumulatively served over 53 million small and micro-sized enterprises (SMEs) as of the end of 2023. The report also highlights MYbank’s continued investment in technology, with 36% of its operating expenses allocated to tech and over 64% of its workforce comprising of tech talents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430942970/en/ MYbank makes financing more accessible for 53 million SMEs (Graphic: Business Wire) “MYbank remains committed to supporting SMEs’ funding needs amidst ongoing economic and technological transformations. As a technology-driven bank, MYbank will enhance its capabilities through continuous exploration of AI and other emerging technologies, aiming to make finance more inclusive for all,” said MYbank President Feng Liang. Leveraging Ant Group’s sel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom